| Stage | CME | % of rev | TOP | % of rev | Gap · A − B |
|---|---|---|---|---|---|
| Revenue | $1.7B | 100.00% | $2M | 100.00% | CME ×786.12 |
| Gross profit | $1.5B | 86.51% | $2M | 100.00% | TOP +13.5pp |
| Operating income | $1.1B | 65.70% | $274,346 | 12.41% | CME +53.3pp |
| Pre-tax income | $1.4B | 77.98% | $274,346 | 12.41% | CME +65.6pp |
| Net income | $1.0B | 59.68% | $274,263 | 12.41% | CME +47.3pp |
| Stage | CME | TOP | Gap · A − B |
|---|---|---|---|
| Revenue | $1.7B100.00% | $2M100.00% | CME ×786.12 |
| Gross profit | 86.51%$1.5B | 100.00%$2M | TOP +13.5pp |
| Operating income | 65.70%$1.1B | 12.41%$274,346 | CME +53.3pp |
| Pre-tax income | 77.98%$1.4B | 12.41%$274,346 | CME +65.6pp |
| Net income |
| 59.68%$1.0B |
| 12.41%$274,263 |
| CME +47.3pp |
No shared counterparties.